Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
 
00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]ICU2/1940/198Improvement, RR [CI]TreatmentControlCadegiani88%0.12 [0.01-2.52]death0/3572/137Elalfy87%0.13 [0.06-0.27]viral+7/6244/51CT​1Silva (SB RCT)26%0.74 [0.38-1.41]viral+23 (n)13 (n)Rossignol (DB RCT)-206%3.06 [0.13-74.6]death1/1840/195Tau​2 = 1.35; I​2 = 77.4%Early treatment49%0.51 [0.13-1.95]10/82046/59449% improvementBlum (DB RCT)67%0.33 [0.07-1.50]death2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies55%0.45 [0.15-1.35]12/84552/61955% improvement6 nitazoxanide COVID-19 studiesc19nitazoxanide.com Sep 24, 20211 CT: study uses combined treatmentTau​2 = 1.03; I​2 = 71.7%; Z = 1.42Effect extraction pre-specifiedFavors nitazoxanideFavors control
Database of all nitazoxanide COVID-19 studies. Submit updates/corrections.
Sep 11
N/A Walker et al., medRxiv, doi:10.1101/2021.09.10.21263376 (Preprint) An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Details   Phase I trial of high dose nitazoxanide, 1500mg twice daily, with 14 participants. Trreatment was safe and well tolerated. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro targ..
Aug 10
News Calderón et al., News Report (News) news Mantiene Hospital Mónica Pretelini bajo índice de muertes Covid de mujeres embarazadas
Details   News report on the use of nitazoxanide for pregnant COVID-19 patients in a clinic in Mexico, reporting significant improvements in hospitalization and mortality compared to locations without treatment.
May 13
Late Enríquez López et al., Cureus, doi:10.7759/cureus.15002 (Peer Reviewed) Evolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital
Details   Case study of 51 COVID-19 positive pregnant women in Mexico treated with nitazoxanide, showing much better survival compared to hospitals not using nitazoxanide.
Apr 20
Early Rossignol et al., medRxiv, doi:10.1101/2021.04.19.21255441 (Preprint) death, ↑206.0%, p=0.49 Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Details   RCT with 184 outpatients treated with an extended release formulation of nitazoxanide, and 195 controls, showing lower hospitalization and progression to severe disease with treatment. There was one COVID-19 related death in the treatment..
Mar 5
Early Silva et al., medRxiv, doi:10.1101/2021.03.03.21252509 (Preprint) viral+, ↓26.5%, p=0.36 Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study
Details   Small RCT with 23 nitazoxanide and 13 control patients showing significantly more patients achieved over 35% reduction in viral load from baseline. NCT04463264.
Feb 16
Early Elalfy et al., J. Med. Virol., doi:10.1002/jmv.26880 (Peer Reviewed) viral+, ↓86.9%, p<0.0001 Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-1
Details   Non-randomized controlled trial with 62 mild and early moderate patients with home treatment with ivermectin + nitazoxanide + ribavirin + zinc, showing significantly faster viral clearance.
Jan 22
Late Blum et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.100981 (preprint 1/22) (Peer Reviewed) death, ↓66.7%, p=0.25 Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial
Details   RCT with 25 nitazoxanide patients and 25 control patients, showing improved virological and clinical outcomes with treatment. Authors also perform an in vitro study in Vero E6 cells showing 90% inhibition with 0.5µM, with no cytotoxicity..
Nov 4
2020
Early Cadegiani et al., New Microbes and New Infections, doi:10.1016/j.nmni.2021.100915 (preprint 11/4/2020) (Peer Reviewed) death, ↓87.8%, p=0.08 Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in Outpatient Settings Significantly Improved COVID-19 outcomes compared to Known outcomes in untreated patients
Details   Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated COVID-19 population, ev..
Oct 23
2020
Early Rocco et al., European Respiratory Journal, doi:10.1183/13993003.03725-2020 (preprint 10/23/20) (Peer Reviewed) ICU, ↑404.1%, p=0.24 Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial (preprint 10/23)
Details   RCT 392 patients, median treatment delay 5 days, showing improved viral recovery at 5 days. Symptom recovery was no different at 5 days, and the treatment arm had two ICU admissions compared to zero for control. There were no serious adve..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit